John Valliant
2022
In 2022, John Valliant earned a total compensation of $2.7M as Chief Executive Officer at Fusion Pharmaceuticals, a 16% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $238,119 |
|---|---|
| Option Awards | $1,881,826 |
| Salary | $595,284 |
| Other | $31,314 |
| Total | $2,746,543 |
Valliant received $1.9M in option awards, accounting for 69% of the total pay in 2022.
Valliant also received $238.1K in non-equity incentive plan, $595.3K in salary and $31.3K in other compensation.
Rankings
In 2022, John Valliant's compensation ranked 1,332nd out of 5,736 executives tracked by ExecPay. In other words, Valliant earned more than 76.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,332 out of 5,736 | 77th |
Division Manufacturing | 657 out of 3,125 | 79th |
Major group Chemicals And Allied Products | 243 out of 1,416 | 83rd |
Industry group Drugs | 222 out of 1,317 | 83rd |
Industry Biological Products, Except Diagnostic Substances | 55 out of 291 | 81st |
Source: SEC filing on April 27, 2023.
Valliant's colleagues
We found two more compensation records of executives who worked with John Valliant at Fusion Pharmaceuticals in 2022.